TFS Trial Form Support
TFS Trial Form Support is recorded as a service provider in 17 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 17 of 17 trials · Latest update first
Microdystrophin (GNT0004) Gene Therapy Clinical Trial in Duchenne Muscular Dystrophy: A phase I/II/III study with a dose determination part followed by an efficacy and safety evaluation, quadruple blind placebo-controlled part and then by a long term safety follow up part, in ambulant boys
Sponsor Genethon
- Start (EU)
- Latest update
- Estimated end
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Sponsor Eyebiotech Limited
- Start (EU)
- Latest update
- Estimated end
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Sponsor Eyebiotech Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2, multicentre, open-label study to explore the effects of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris
Sponsor MoonLake Immunotherapeutics AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multicenter, prospective, randomized, placebo and Non-Surgical Standard of Care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)
Sponsor Mediwound Ltd.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase inhibitor in patients with previously treated unresectable solid tumours
Sponsor iOmx Therapeutics AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm2 and up to 100 cm2 in Adult Patients With Actinic Keratosis
Sponsor Almirall S.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp
Sponsor Almirall S.A.
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, 3-ARM PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL EYE103 COMPARED WITH INTRAVITREAL RANIBIZUMAB (0.5MG) IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA
Sponsor Eyebiotech Limited
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ADAPTIVE PHASE III TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF VILOBELIMAB IN THE TREATMENT OF ULCERATIVE PYODERMA GANGRENOSUM
Sponsor InflaRx GmbH
- Start (EU)
- Latest update
- Estimated end
An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient treatment modality in metastatic or advanced colorectal cancer (mCRC) patients with acquired FOLFIRI resistant cancer disease
Sponsor Scandion Oncology A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, open-label, imaging study to explore the effects of sonelokimab in patients with active psoriatic arthritis or axial spondyloarthritis
Sponsor MoonLake Immunotherapeutics AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)
Sponsor Astellas Pharma Global Development Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-masked, Multi-center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema
Sponsor Eyebiotech Limited
- Start (EU)
- Latest update
- Estimated end
A phase I/II trial of IOMX-0675 a fully human monoclonal antibody selectively inhibiting LILRB1/2 alone or in combination with pembrolizumab in patients with previously treated advanced/metastatic solid tumors (LIMNOS)
Sponsor iOmx Therapeutics AG
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 2 open-label imaging study to explore the effects of sonelokimab in patients with active axial spondyloarthritis
Sponsor MoonLake Immunotherapeutics AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.7881 in adult patients with moderate-to-severe atopic dermatitis
Sponsor Bioprojet Pharma
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for TFS Trial Form Support?
The 2026-10-09 snapshot links TFS Trial Form Support to 17 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Safety reporting & pharmacovigilance, Medical writing, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for TFS Trial Form Support?
The most frequently recorded therapeutic areas are Dermatology, Ophthalmology, Genetic and Congenital Disorders, Immunology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to TFS Trial Form Support conducted?
The linked trials record locations in 16 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where TFS Trial Form Support delivered services.
What can this page tell me about TFS Trial Form Support's trial experience?
Browse 17 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under TFS Trial Form Support. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- TFS Trial Form Support AB